230 completed, 50 terminated, 32 active not recruiting, 32 recruiting. 391 Phase 3, 63 Phase 2.
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project Cetirizine, Diphenhydramine - Multiple Sclerosis | Phase 3 | Not yet recruiting | University of Miami | 60 | 2026-11-01 | 2026-10-02 |
| A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Kedrion S.p.A. | 161 | 2026-11-01 | 2026-11-05 |
| A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 2 / Phase 3 | Not yet recruiting | argenx | 6 | 2026-09-01 | 2026-06-10 |
| Online Mindfulness-Based Cognitive Therapy for People With Multiple Sclerosis With Mild-Moderate Depression Mindfulness-Based Cognitive Therapy - Multiple Sclerosis | Phase 3 | Not yet recruiting | Robert Simpson | 152 | 2026-08-01 | 2026-08-03 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research Privosegtor, Methylprednisolone, Placebo - Optic Neuritis | Phase 3 | Recruiting | Oculis | 210 | 2026-05-28 | 2026-08-14 |
| A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Recruiting | Hoffmann-La Roche | 8 | 2026-05-06 | 2026-10-01 |
| A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 | Recruiting | Grifols Therapeutics LLC | 40 | 2026-04-02 | 2026-11-10 |
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis Orelabrutinib, Placebo - Secondary Progressive Multiple Sclerosis | Phase 3 | Recruiting | Zenas BioPharma (USA), LLC | 990 | 2026-03-23 | 2026-11-04 |
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis Orelabrutinib, Placebo - Multiple Sclerosis (MS) Primary Progressive | Phase 3 | Recruiting | Zenas BioPharma (USA), LLC | 705 | 2026-03-23 | 2026-11-10 |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis Frexalimab, MRI contrast-enhancing preparations - Multiple Sclerosis | Phase 3 | Recruiting | Sanofi | 160 | 2026-01-14 | 2026-10-13 |
| Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder Eculizumab administration, High-dose corticosteroid pulse therapy, Plasma exchange (PE) - Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Recruiting | Tianjin Medical University General Hospital | 198 | 2026-01-01 | 2026-05-14 |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Remibrutinib (blinded), Placebo, Remibrutinib (Open label) - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 1275 | 2025-11-11 | 2026-10-13 |
| A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis BCD-281, Ocrelizumab - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Recruiting | Biocad | 292 | 2025-11-01 | 2026-01-06 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Empasiprubart IV, Placebo IV - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 160 | 2025-09-16 | 2026-11-09 |
| An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Tanruprubart - Guillain-Barre Syndrome | Phase 3 | Recruiting | Annexon, Inc. | 30 | 2025-09-12 | 2026-10-26 |
| Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD Slow-tapering glucocorticoids + Inebilizumab, Rapid-tapering glucocorticoids + Inebilizumab - Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Not yet recruiting | Tianjin Medical University General Hospital | 170 | 2025-09-01 | 2025-08-20 |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP empasiprubart, IVIg, empasiprubart-placebo - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 218 | 2025-08-22 | 2026-11-03 |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX - Optic Neuritis, Myelitis | Phase 3 | Recruiting | Mayo Clinic | 382 | 2025-07-11 | 2026-09-24 |
Showing 20 of 391. Sign in to see all of them.
Multiple Sclerosis (238) · Multiple Sclerosis, Relapsing-Remitting (97) · Multiple Sclerosis, Chronic Progressive (38) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (31) · Neuromyelitis Optica (25) · Muscle Spasticity (20) · Recurrence (19) · Optic Neuritis (15) · Adrenoleukodystrophy (9) · Guillain-Barre Syndrome (8) · Myelitis, Transverse (8) · Rare Diseases (8) · Pain (7) · Fatigue (6)
Nervous System Diseases (386) · Autoimmune Diseases (376) · Immune System Diseases (376) · Autoimmune Diseases of the Nervous System (375) · Demyelinating Autoimmune Diseases, CNS (338) · Pathological Conditions, Signs and Symptoms (142) · Pathologic Processes (103) · Disease Attributes (99) · Chronic Disease (78) · Multiple Sclerosis (74) · Signs and Symptoms (49) · Neuromuscular Diseases (46) · Neurologic Manifestations (44) · Peripheral Nervous System Diseases (40)
ocrelizumab (29) · Interferon beta-1a (24) · Glatiramer Acetate (18) · nabiximols (18) · teriflunomide (17) · Dimethyl Fumarate (16) · Fingolimod Hydrochloride (16) · Rituximab (15) · 4-Aminopyridine (14) · Methylprednisolone (12) · Natalizumab (11) · Immunoglobulins, Intravenous (9) · Alemtuzumab (8) · Cladribine (7) · Interferon beta-1b (6)
Biogen (37) · Hoffmann-La Roche (19) · Novartis Pharmaceuticals (16) · Jazz Pharmaceuticals (14) · Sanofi (14) · Teva Branded Pharmaceutical Products R&D, Inc. (10) · Alexion Pharmaceuticals, Inc. (8) · EMD Serono (8) · Biocad (7) · Acorda Therapeutics (6) · Bayer (5) · Genzyme, a Sanofi Company (5) · Novartis (5) · RVL Pharmaceuticals, Inc. (5) · Rennes University Hospital (5)
United States (196) · France (122) · Canada (120) · Germany (119) · Poland (116) · Italy (111) · United Kingdom (107) · Spain (102) · Czechia (85) · Belgium (69) · Russia (66) · Turkey (Türkiye) (63) · Australia (61) · Bulgaria (60) · Ukraine (58)
Bettina Stubinski, MD (3) · Bonnie Faust (3) · Fernando Dangond, MD (3) · Michael Panzara, MD, MPH (3) · Andrew Blight, PhD (2) · Ayman Tourbah, MD, PhD (2)
PMID 25475413, PMID 27733070, PMID 33023488, PMID 37652990, PMID 40258203, PMID 42328798, PMID 25245812, PMID 26932146, PMID 30918100, PMID 31654272, PMID 31675266, PMID 31762387, PMID 32426039, PMID 32447743, PMID 32539719, PMID 32710396, PMID 33414927, PMID 34035833, PMID 34376508, PMID 34882037, PMID 35003076, PMID 36163349, PMID 36619856, PMID 37745914, PMID 39935588, PMID 40743487, PMID 42578463, PMID 15327042, PMID 23531349, PMID 24131282, PMID 26000222, PMID 26121423, PMID 26526385, PMID 27411694, PMID 27590291, PMID 28002688, PMID 28304217, PMID 28680917, PMID 28751099, PMID 28770420, PMID 28835401, PMID 30144037, PMID 31144568, PMID 32757523, PMID 33676197, PMID 33969750, PMID 34370275, PMID 34378446, PMID 34498507, PMID 35019731
2023 (15), 2015 (9), 2014 (8), 2018 (8), 2019 (7), 2009 (6), 2016 (5), 2017 (5), 2008 (4), 2025 (4), 2004 (2), 2005 (1), R21HD091836 (1), U01NS045719 (1), UM1AI109565 (1)